NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

REGN

Regeneron Pharmaceuticals, Inc

May 22 • 04:00PM ET

596.85

Dollar change -7.77
Percentage change -1.29	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ SPY IVV VTV XLV IBB JEPI COWZ

Scroll to Statements

Index	NDX, S&P 500	P/E	15.19	EPS (ttm)	39.29	Insider Own	3.61%	Shs Outstand	106.40M	Perf Week	2.03%
Market Cap	64.44B	Forward P/E	15.12	EPS next Y	39.48	Insider Trans	0.00%	Shs Float	104.06M	Perf Month	1.53%
Income	4.50B	PEG	8.08	EPS next Q	8.53	Inst Own	87.04%	Short Float	2.77%	Perf Quarter	-14.78%
Sales	14.09B	P/S	4.57	EPS this Y	-21.87%	Inst Trans	3.63%	Short Ratio	2.51	Perf Half Y	-21.67%
Book/sh	271.60	P/B	2.20	EPS next Y	10.76%	ROA	12.51%	Short Interest	2.89M	Perf Year	-39.55%
Cash/sh	77.33	P/C	7.72	EPS next 5Y	1.88%	ROE	15.96%	52W Range	520.50 - 1211.20	Perf YTD	-16.21%
Dividend Est.	2.83 (0.47%)	P/FCF	20.77	EPS past 5Y	15.74%	ROI	14.02%	52W High	-50.72%	Beta	0.38
Dividend TTM	1.76 (0.29%)	Quick Ratio	4.03	Sales past 5Y	22.10%	Gross Margin	82.28%	52W Low	14.67%	ATR (14)	22.73
Dividend Ex-Date	May 20, 2025	Current Ratio	4.93	EPS Y/Y TTM	15.65%	Oper. Margin	28.11%	RSI (14)	52.06	Volatility	2.13% 3.74%
Employees	15106	Debt/Eq	0.09	Sales Y/Y TTM	7.52%	Profit Margin	31.94%	Recom	1.57	Target Price	806.00
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	15.94%	Payout	0.00%	Rel Volume	0.75	Prev Close	604.62
Sales Surprise	-6.74%	EPS Surprise	-4.66%	Sales Q/Q	-3.70%	Earnings	Apr 29 BMO	Avg Volume	1.15M	Price	596.85
SMA20	2.13%	SMA50	-0.61%	SMA200	-25.85%	Trades		Volume	867,153	Change	-1.29%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976
Mar-24-23	Upgrade	Jefferies	Hold → Buy	$675 → $925
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform	$775 → $875
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight	$850

Show Previous Ratings

Today 05:00PM	Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
10:18AM	Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A "Very Smart Deal," Says Jim Cramer (Insider Monkey)
May-21-25 10:51AM	Viz.ai, Sanofi and Regeneron to link for COPD management (Pharmaceutical Technology)
05:45AM	Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal (Benzinga)
May-20-25 05:06PM	S&P 500 Gains and Losses Today: FICO Stock Falls as Federal Housing Official Questions Pricing (Investopedia)
12:12PM	Loading…
12:12PM	ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care (Pharmaceutical Technology)
11:35AM	Evercore says 23andMe buyout removes downside case for OraSure (TipRanks)
09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks)
07:30AM	Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD) (Business Wire)
06:48AM	Jamie Dimons Tariffs Warning Should Have Rocked Markets. Why Hes Being Ignored. (Barrons.com)
04:59AM	Company News for May 20, 2025 (Zacks)
May-19-25 04:42PM	Regeneron to acquire bankrupt genetic tester 23andMe (Yahoo Finance Video)
03:29PM	Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal (Benzinga)
02:30PM	Squawk Pod: Walter Isaacson & Business Roundtable CEO Josh Bolten - 05/19/25 Audio Only (CNBC TV)
01:52PM	Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million (The Wall Street Journal)
12:42PM	Loading…
12:42PM	Regeneron Buys 23andMe in Bankruptcy Auction (Investopedia)
12:24PM	Regeneron buys bankrupt 23andMe for $256m (Pharmaceutical Technology)
12:13PM	Regeneron Is Buying 23andMe. The Deal Is a Head-Scratcher. (Barrons.com)
11:51AM	Regeneron agrees to purchase bankrupt 23andMe, protect data (CFO Dive)
11:45AM	Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal (Fox Business)
10:32AM	23andMe just got bought out of bankruptcy (Quartz)
09:38AM	23andMe to be acquired by Regeneron (Yahoo Finance)
09:33AM	23andMe sells gene-testing business to DNA drug maker Regeneron (LA Times)
09:28AM	Regeneron Pharmaceuticals to Acquire 23andMe for $256M (Insider Monkey)
09:00AM	Biotechnology company Regeneron buying 23andMe for $256 million (Associated Press Finance)
08:55AM	23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction (Investor's Business Daily)
08:21AM	Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million (CNN Business)
07:43AM	Regeneron agrees to buy bankrupt 23andMe, promises ethical use of customers' DNA data (Reuters)
07:07AM	Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness (GlobeNewswire)
07:04AM	Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale (GlobeNewswire)
11:24AM	Loading…
May-16-25 11:24AM	75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition (GlobeNewswire)
06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive)
May-15-25 02:02PM	Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments (GlobeNewswire)
07:54AM	Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025 (MarketBeat)
May-14-25 07:02PM	Regeneron Upgraded as AbbVie Catches Policy Heat (GuruFocus.com)
10:24AM	Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck. (Barrons.com)
May-13-25 09:56AM	Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales (Zacks)
08:10AM	Best Biotech Stocks to Buy in 2025 (MarketBeat)
May-10-25 11:00AM	Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Blue Chip Stock to Buy? (Insider Monkey)
May-09-25 12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
10:47AM	Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'Numbers Came Up A Little Short' (Insider Monkey)
12:37AM	1 Cash-Heavy Stock on Our Buy List and 2 to Ignore (StockStory)
May-08-25 09:48AM	Regeneron Pharmaceuticals, Inc. (REGN): Among the Cheap ESG Stocks to Buy According to Hedge Funds (Insider Monkey)
May-07-25 10:45AM	Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
08:20AM	Regeneron Pharmaceuticals (REGN): Among Billionaire Mario Gabelli's Large-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
May-05-25 04:51PM	Kiniksa Pharmaceuticals: Making Steady Progress (Seeking Alpha) -7.47%
May-02-25 10:51AM	Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y (Zacks)
09:42AM	4 Dividend Stocks to Buy on the Pullback (Motley Fool)
May-01-25 03:40PM	Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'Arguably The Most Innovative Biopharma Company I've Seen In The Last Two Decades' (Insider Monkey)
10:20AM	Regeneron price target lowered to $940 from $975 at Truist (TipRanks)
09:30AM	Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination (GlobeNewswire)
09:00AM	Dupixent (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases (GlobeNewswire)
Apr-30-25 12:56PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research) +5.25%
09:10AM	Company News for Apr 30, 2025 (Zacks)
03:08AM	Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call Highlights: Strong Dupixent Sales ... (GuruFocus.com)
01:15AM	Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-29-25 05:05PM	S&P 500 Gains and Losses Today: NXP Semiconductors Stock Falls as CEO Plans Departure (Investopedia) -6.87%
04:13PM	Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down (Investor's Business Daily)
03:46PM	SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO (Seeking Alpha)
02:52PM	Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides (Benzinga)
02:43PM	Why Regeneron (REGN) Stock Is Falling Today (StockStory)
01:32PM	Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates (Investopedia)
01:22PM	Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down (Zacks)
12:30PM	Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
11:53AM	Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More (Investopedia)
10:29AM	Regeneron Stock Plummets After Earnings Miss (Barrons.com)
09:42AM	Regeneron Crashes 10% After Eylea Miss Drags Its Earnings Report (Investor's Business Daily)
09:30AM	Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:27AM	Regeneron's first-quarter results miss on lower Eylea demand (Reuters)
07:40AM	Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates (Zacks)
06:40AM	Regeneron: Q1 Earnings Snapshot (Associated Press Finance)
06:39AM	Regeneron (NASDAQ:REGN) Misses Q1 Sales Targets (StockStory)
06:32AM	The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron (Zacks)
06:30AM	Regeneron Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
05:35AM	EC conditionally approves Regenerons Lynozyfic for multiple myeloma (Pharmaceutical Technology)
02:15AM	Alphabet Sets A Positive Tone Ahead Of Mega Tech Earnings Results This Week (Seeking Alpha)
Apr-28-25 07:08PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
12:08PM	Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts? (Zacks)
07:38AM	Regeneron expands US manufacturing with $3B Fujifilm partnership (Manufacturing Dive)
07:01AM	Lynozyfic (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
07:00AM	EYLEA HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease (GlobeNewswire)
03:04AM	Regeneron (REGN) Reports Earnings Tomorrow: What To Expect (StockStory)
Apr-26-25 09:30AM	Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold (Motley Fool)
Apr-24-25 11:37AM	Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs (Zacks)
10:01AM	Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
09:15AM	What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 Earnings (Zacks)
07:59AM	Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth (Zacks)
Apr-23-25 12:37PM	Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More (Zacks)
Apr-22-25 02:29PM	Regeneron to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
11:13AM	Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom (Barrons.com)
10:25AM	Regeneron partners with Fujifilm to broaden manufacturing capacity (Pharmaceutical Technology)
10:01AM	Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:40AM	Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (Seeking Alpha)
06:51AM	Drug Companies Step Up 'Make in America' Plans to Counter Tariffs (The Wall Street Journal)
06:16AM	Regeneron to invest over $3 billion to boost US manufacturing (Reuters)
06:00AM	Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines (GlobeNewswire)
06:00AM	FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion (Business Wire)
Apr-21-25 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
09:22AM	Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria (Zacks)
05:10AM	Sanofi and Regenerons dupilumab approved by FDA for urticaria (Pharmaceutical Technology)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SING GEORGE L	Director	Dec 31 '24	Option Exercise	413.33	3,338	1,379,696	29,610	Jan 03 04:02 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Nov 05 04:23 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Sale	844.61	1,000	844,610	12,931	Nov 05 04:23 PM
MARION E MCCOURT	Officer	Nov 01 '24	Proposed Sale	844.61	1,000	844,610		Nov 01 04:38 PM
RYAN ARTHUR F	Director	Oct 01 '24	Sale	1048.78	100	104,878	17,582	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Sale	1054.06	1,000	1,054,060	12,931	Oct 03 04:02 PM
MARION E MCCOURT	Officer	Oct 01 '24	Proposed Sale	1054.06	1,000	1,054,060		Oct 01 04:13 PM
McCourt Marion	EVP Commercial	Sep 03 '24	Option Exercise	381.40	1,000	381,400	13,931	Sep 05 04:01 PM
McCourt Marion	EVP Commercial	Sep 03 '24	Sale	1178.73	1,000	1,178,730	12,931	Sep 05 04:01 PM
RYAN ARTHUR F	Director	Sep 03 '24	Sale	1178.68	100	117,868	17,682	Sep 05 04:01 PM
MARION E MCCOURT	Officer	Sep 03 '24	Proposed Sale	1178.73	1,000	1,178,730		Sep 03 04:04 PM
Fenimore Christopher R.	SVP Finance & CFO	Aug 28 '24	Sale	1205.33	5,680	6,846,262	0	Aug 29 04:27 PM
Christopher Fenimore	Officer	Aug 28 '24	Proposed Sale	1205.21	5,680	6,845,565		Aug 28 04:35 PM
Bassler Bonnie L	Director	Aug 15 '24	Option Exercise	371.40	756	280,778	2,138	Aug 19 04:02 PM
Bassler Bonnie L	Director	Aug 15 '24	Sale	1170.00	756	884,520	1,382	Aug 19 04:02 PM
POON CHRISTINE A	Director	Aug 15 '24	Option Exercise	413.33	10,838	4,479,671	13,010	Aug 19 04:01 PM
POON CHRISTINE A	Director	Aug 15 '24	Sale	1158.17	10,838	12,552,284	2,172	Aug 19 04:01 PM
Christine Poon	Director	Aug 15 '24	Proposed Sale	1156.86	10,838	12,538,049		Aug 15 05:55 PM
MURPHY ANDREW J	EVP Research	Aug 13 '24	Option Exercise	399.66	20,000	7,993,200	68,306	Aug 15 04:01 PM
MURPHY ANDREW J	EVP Research	Aug 14 '24	Sale	1153.15	6,363	7,337,505	48,306	Aug 15 04:01 PM
Bassler Bonnie L	Director	Aug 15 '24	Proposed Sale	1170.00	756	884,520		Aug 15 11:45 AM
MURPHY ANDREW J	Officer	Aug 14 '24	Proposed Sale	1152.27	6,363	7,331,894		Aug 14 04:08 PM
STAHL NEIL	EVP Research and Development	Aug 08 '24	Sale	1084.54	5,197	5,636,346	50,999	Aug 12 04:05 PM
Neil Stahl	Officer	Aug 08 '24	Proposed Sale	1084.46	5,197	5,635,926		Aug 08 04:53 PM
Pitofsky Jason	VP Controller	Aug 07 '24	Option Exercise	372.46	487	181,388	4,691	Aug 07 04:40 PM
Pitofsky Jason	VP Controller	Aug 07 '24	Sale	1070.00	487	521,090	4,204	Aug 07 04:40 PM
Jason Pitofsky	Officer	Aug 07 '24	Proposed Sale	1069.75	487	520,970		Aug 07 04:33 PM
STAHL NEIL	EVP Research and Development	Aug 02 '24	Option Exercise	555.67	23,638	13,134,927	74,637	Aug 06 04:03 PM
Bassler Bonnie L	Director	Aug 02 '24	Option Exercise	371.40	756	280,778	2,138	Aug 05 04:05 PM
Bassler Bonnie L	Director	Aug 02 '24	Sale	1115.00	756	842,940	1,382	Aug 05 04:05 PM
McCourt Marion	EVP Commercial	Aug 01 '24	Option Exercise	372.46	1,137	423,487	14,068	Aug 05 04:04 PM
McCourt Marion	EVP Commercial	Aug 01 '24	Sale	1060.86	1,137	1,206,198	12,931	Aug 05 04:04 PM
RYAN ARTHUR F	Director	Aug 01 '24	Sale	1100.03	1	1,100	17,782	Aug 05 04:01 PM
RYAN ARTHUR F	Director	Aug 01 '24	Sale	1085.53	99	107,467	17,783	Aug 05 04:01 PM
Bassler Bonnie L	Director	Aug 02 '24	Proposed Sale	1115.00	756	842,940		Aug 02 10:43 AM
MARION E MCCOURT	Officer	Aug 01 '24	Proposed Sale	1060.86	1,137	1,206,198		Aug 01 04:18 PM
Arthur F. Ryan	Director	Aug 01 '24	Proposed Sale	1079.19	300	323,757		Aug 01 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jul 11 '24	Sale	1088.95	1,866	2,031,981	37,937	Jul 12 04:00 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Option Exercise	372.46	1,137	423,487	14,068	Jul 02 04:01 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Sale	1047.11	1,137	1,190,564	12,931	Jul 02 04:01 PM
RYAN ARTHUR F	Director	Jul 01 '24	Sale	1059.24	100	105,924	17,882	Jul 02 04:01 PM
Bassler Bonnie L	Director	Jun 24 '24	Option Exercise	371.40	756	280,778	2,138	Jun 25 04:41 PM
Bassler Bonnie L	Director	Jun 24 '24	Sale	1062.00	756	802,872	1,382	Jun 25 04:41 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jun 24 '24	Option Exercise	555.67	14,450	8,029,431	50,887	Jun 25 04:39 PM
BROWN MICHAEL S	Director	Jun 14 '24	Option Exercise	625.60	1,535	960,296	2,917	Jun 17 04:01 PM
BROWN MICHAEL S	Director	Jun 14 '24	Sale	1040.00	1,535	1,596,400	1,382	Jun 17 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 12 '24	Sale	1015.94	16,149	16,406,406	0	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 11 '24	Sale	1015.43	9,064	9,203,823	55,134	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 06 '24	Sale	1015.02	787	798,821	64,198	Jun 10 04:03 PM
Bassler Bonnie L	Director	Jun 05 '24	Option Exercise	380.95	827	315,046	2,209	Jun 07 04:06 PM
Bassler Bonnie L	Director	Jun 05 '24	Sale	1011.00	827	836,097	1,382	Jun 07 04:06 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Option Exercise	372.46	1,138	423,859	14,069	Jun 05 04:07 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Sale	980.16	1,138	1,115,422	12,931	Jun 05 04:07 PM
RYAN ARTHUR F	Director	Jun 03 '24	Sale	994.50	100	99,450	17,982	Jun 05 04:06 PM
BROWN MICHAEL S	Director	May 28 '24	Option Exercise	625.60	1,172	733,203	2,554	May 29 04:01 PM
BROWN MICHAEL S	Director	May 28 '24	Sale	974.86	1,172	1,142,536	1,382	May 29 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience